Thiazolidinediones: A review of their benefits and risks

Southern Medical Journal

Volumn 95, Issue 10, 2002, Pages 1188-1194

  Ovalle, Fernando ^a   Ovalle Berúmen, J Fernando ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

BONE MARROW TOXICITY; CARCINOGENESIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER FAILURE; LIVER TOXICITY; LUNG EDEMA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

EID: 0036774734     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200295100-00017     Document Type: Review

References (85)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986
2. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117
3. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853
4. Kannel WB, McGee DL: Diabetes and cardiovascular disease risk factors: The Framingham Study. Circulation 1979; 59:8-13
5. Rubin RJ, Altman WM, Mendelson DN: Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78:809A-809F
6. Donnelly R, Emslie-Smith AM, Gardner ID, et al: Vascular complications of diabetes. BMJ 2000; 320:1062-1066
7. Day C: Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med 1999; 16:179-192
8. Schoonjans K, Auwerx J: Thiazolidinediones: An update. Lancet 2000; 355:1008-1010
9. DeFronzo R: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281-303
10. Defronzo R: Pharmacologic therapy for type 2 diabetes mellitus (Letter). Ann Intern Med 2000; 133:73-74
11. Kumar S, Boulton AJM, Beck-Nielsen H, et al: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39:701-709
12. Maggs DG, Buchanan TA, Burant CF, et al: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 1998; 128:176-185
13. Inzucchi SE, Maggs DG, Spollett GR, et al: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867-872
14. Tack CJ, Smits P, Demacker PNM, et al: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21:796-799
15. Nozue T, Michishita I, Minagawa F, et al: Troglitazone directly increases HDL cholesterol levels. Diabetes Care 1999; 22:355-356
16. Ovalle F, Bell DSH: The effect of thiazolidinediones on HDL subfractions. Diabetes 2000; 49(suppl 1):A269
17. Scheen AJ, Lefébvre PJ: Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22:1568-1577
18. Reginato MJ, Lazar MA: Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 1999; 10:9-13
19. Ogihara T, Rakugi H, Ikegami H, et al: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8:316-320
20. Ghazzi MN, Perez JE, Antonucci TK, et al: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46:433-439
21. Sung BH, Izzo JL, Dandona P, et al: Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999; 34:83-88
22. Iwamoto Y, Kosaka K, Kuzuya T, et al: Effects of troglitazone, a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19:151-156
23. Bakris GL, Dole JF, Porter LE, et al: Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes 2000; 49 (suppl 1):A96
24. Sironi AM, Vichi S, Gastaldelli A, et al: Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997; 62:194-202
25. Claudi T, Starkie M, Frith L, et al: Troglitazone improves cardiovascular risk profile compared with glibencamide. Diabet Med 1997; 14(suppl 4):530
26. Imano E, Kanda T, Nakatani Y, et al: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21:2135-2139
27. Miura Y, Kato Y, Yamamoto N, et al: Troglitazone improves diabetic nephropathy in patients with type 2 diabetes. Diabetes, 2000; 49(suppl 1):A19-A20
28. Bakris G, Weston WM, Rappaport EB, et al: Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes. Diabetologia 1999; 42 (suppl 1):A230
29. Freed MI, Weston WM, Viberti G: Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. Diabetologia 1999; 42(suppl 1):A230
30. Minamikawa J, Tanaka S, Yamauchi M, et al: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83:1818-1820
31. Tagaki T, Yoshida JK, Akasaka T, et al: Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: A serial intravascular ultrasound study (Abstract 886-2). J Am Coll Cardiol 1999; 33:100A
32. Fujishima S, Ohya Y, Nakamura Y, et al: Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens 1998; 11:1134-1137
33. Tack CJJ, Ong MKE, Lutterman JA, et al: Insulin induced vasodilatation and endothelial function in obesity/insulin resistance, effects of troglitazone. Diabetologia 1998; 41:569-576
34. Kubo K: Effects of troglitazone on coagulation-fibrinolysis abnormalities in patients with type II diabetes mellitus. Curr Ther Res Clin Exp 1998; 59:537-544
35. Fonseca VA, Reynolds T, Hemphill D, et al: Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Comp 1998; 4:181-186
36. Ehrmann DA, Schneider DJ, Sobel BE, et al: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108-2116
37. Kelly IE, Han TS, Walsh K, et al: Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22:288-293
38. Mori Y., Murakawa Y, Okada K, et al: Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22:908-912
39. Akasawa S, Sun F, Ito M, et al: Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23:1067-1071
40. Brunzell JD, Hokanson JE: Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22(suppl 3):C10-C13
41. Bonora E: Relationship between regional fat distribution and insulin resistance. Int J Obes 2000; 24(suppl 2):S32-S35
42. Cavaghan MK, Ehrmann DA, Byrne MN, et al: Treatment with the oral antidiabetic agent troglitazone improves β-cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100:530-537
43. Prigeon RL, Kahn SE, Porte D Jr: Effect of troglitazone on βcell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998; 83:819-823
44. Ovalle F, Bell DSH: Thiazolidinedione induced recovery of pancreatic beta cell function. Diabetes 2000; 49(suppl 1):A120
45. Dubois M, Pattou F, Kerr-Conte J, et al: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000; 43:1165-1169
46. Okazaki R, Miura M, Toriumi M, et al: Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocrinol J 1999; 46:795-801
47. Dunaif A, Scott D, Finegood D, et al: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299-3306
48. Ehrmann DA, Schneider DJ, Sobel BE, et al: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108-2116
49. Izumino K, Sakamaki H, Ishibashi M, et al: Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. J Clin Endocrinol Metab 1997; 82:2391-2395
50. Walli R, Michl GM, Muhlbayer D, et al: Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 2000; 199:253-262
51. Arioglu E, Duncan-Morin J, Sebring N, et al: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263-274
52. Brockman JA, Gupta RA, Dubois RN: Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115:1049-1055
53. Kitamura S, Miyazaki Y, Shinomura Y, et al: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90:75-80
54. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4:1004-1005
55. Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in-vitro and in-vivo. Cancer Res 1998; 58:3344-3352
56. Elstner E, Muller C, Koshizucka K, et al: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95:8806-8811
57. Yee LD, Sabourin CL, Liu L, et al: Peroxisome proliferatoractivated receptor gamma activation in human breast cancer. Int J Oncol 1999; 15:967-973
58. Mehta RG, Wiliamson E, Patel MK, et al: A ligand peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92:418-423
59. Tsubouchi Y, Sano H, Kawahito Y, et al: Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270:400-405
60. Takahashi N, Okumura T, Motomura W, et al: Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455:135-139
61. Rubin GL, Zhao Y, Kalus AM, et al: Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy. Cancer Res 2000; 60:1604-1608
62. Demetri GD, Fletcher CD, Mueller E, et al: Induction of solid tumor differentiation by peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96:3951-3956
63. Rezulin (troglitazone) [package insert]. Morris Plains, NJ, Parke-Davis, Division of Warner Lambert Co, 1999
64. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338:916-917
65. Misbin RI: Troglitazone-associated hepatic failure. Ann Intern Med 1999; 130:330
66. Gitlin N, Julie NL, Spurr CL, et al: Two cases of severe clinical and histologic hepatic toxicity associated with troglitazone. Ann Intern Med 1998; 129:36-38
67. Neuschwander-Tetri BA, Isley WI, Oki JC, et al: Troglitazone-induced failure leading to liver transplantation. Ann Intern Med 1998; 129:38-41
68. Vella A, de Groen PC, Dinneon SF: Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129:1080
69. Bell DSH, Ovalle F: Late-onset troglitazone-induced hepatic dysfunction. Diabetes Care 2000; 23:128-129
70. Bailey CJ: The rise and fall of troglitazone. Diabet Med 2000; 17:414-415
71. Forman L, Dimmans DA, Diamond RH: Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132:118-121
72. Al-Salman J, Arjomand H, Kemp DG, et al: Hepatocellular injury in a patient receiving rosiglitazone: A case report. Ann Intern Med 2000; 132:121-124
73. Freid J, Everitt D, Boscia J: Rosiglitazone and hepatic failure. Ann Intern Med 2000; 132:164
74. Avandia (rosiglitazone) [package insert]. Philadelphia, Pa, SmithKline Beecham Co, 1999
75. Actos (pioglitazone) [package insert]. Lincolnshire, III, Takeda Pharmaceutical of America Inc, 2000
76. Matsumoto K, Miyake S, Yano M, et al: Increase of lipoprotein (a) with troglitazone. Lancet 1997; 350:1748-1749
77. Ovalle F, Bell DSH: Troglitazone's effect on lipoprotein (a) levels. Diabetes Care 1999; 22:859-860
78. Williams GD, Deldar A, Jordan WH, et al: Subchronic toxicity of the thiazolidinedione Tanabe-174 (LY282449), in the rat and dog. Diabetes 1993; 42:186A
79. Hirsch IB, Kelly J, Cooper S: Pulmonary edema associated with troglitazone therapy. Arch Intern Med 1999; 159:1811
80. Gorson DM: Significant weight gain with Rezulin therapy. Arch Intern Med 1999; 159:99
81. Breider MA, Gough AW, Haskins JR, et al: Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 1999; 27:545-552
82. Duddy SK, Parker RF, Bleavins MR, et al: P53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Toxicol Appl Pharmacol 1999; 156:106-112
83. Tsibris JC, Porter KB, Jazayeri A, et al: Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor gamma, retinoid X receptor alpha, and all-trans retinoic acid than myometrium. Cancer Res 1999; 59:5737-5744
84. Lefebvre A, Chen I, Desreumaux P, et al: Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APC-/+ mice. Nat Med 1998; 4:1053-1057
85. Saez E, Tontonoz P, Nelson MC, et al: Activators of the nuclear receptor PPARgmnma enhance colon polyp formation. Nat Med 1998; 4:1058-1061